Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Biotricity achieves positive EBITDA in Q2 2025, poised for growth

Biotricity's Q2 2025 performance showcased positive EBITDA, revenue growth, and operational improvements.
The company's strategic strengths lie in expanding capabilities, forming partnerships, and meeting market demand.
Challenges include sustaining profitability, reducing expenses, and navigating competitive pressures.
Opportunities for Biotricity include growth through partnerships, revenue model optimization, and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. It operates through the following segments: Resting (Non-stress) ECG Systems, Stress ECG Systems, and Holter Monitoring Systems. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. The pilot program will demonstrate the value of Biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network.

Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network

After losing some value lately, a hammer chart pattern has been formed for Biotricity (BTCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

REDWOOD CITY, CA / ACCESSWIRE / April 2, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues. There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue.

Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Lobo EV Technologies Ltd

ORLANDO, FL / ACCESSWIRE / March 28, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 30, at 7 p.m.

LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

REDWOOD CITY, CA / ACCESSWIRE / March 28, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership with yet another leading Group Purchasing Organization (GPO). GPOs streamline purchasing processes for medical providers and systems.

Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals

REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the most highly anticipated charity concerts for healthcare access and awareness. Experience the rhythm of life like never before at the Health Aid Africa charity concert, where the thrill of music meets the heart of wellness, thanks to a pioneering partnership with Biotricity Inc. Set against the backdrop of the world's most renowned stadium, this event offers more than just spectacular musical acts-it presents a life-saving opportunity.

Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Biotricity Inc. (BTCY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)

Biotricity's AI automation engine has already proven to increase operational efficiency and support growth, evidenced by the Company's recent margin improvement The Healthcare AI Market is projected to soar to $208.2 billion and remote patient monitoring (RPM) market anticipated to reach $96.67 billion by 2030 Biotricity is now expanding its Cardiac AI platform, building anonymized clinical models to support clinical decisions with expectations to file for FDA by the end of the year REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company reshaping the landscape of medical diagnostic and consumer healthcare, announces expansion of its Cardiac AI Cloud platform: the company is building a cardiac AI clinical model which distills important information to support clinician in cases that require clinical intervention or review. The company expects to file an FDA clearance for its clinical model by the end of the year.

Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud

Biotricity Inc. (BTCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know

REDWOOD CITY, CA / ACCESSWIRE / March 5, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced its partnership with another of the nation's top Group Purchasing Organizations (GPOs). This strategic move solidifies Biotricity's presence in the healthcare landscape and broadly expands market access for the Company in 2024.

Biotricity Partners with a Second Top Group Purchasing Organization - Positions Company for Expanded Market Access to 1 out of every 2 Hospitals in America

Mountain Crest Acquisition Corp II

ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET).

Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Well Positioned to Enter US $1.56 Billion Canadian Cardiology Devices Market REDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, proudly announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering US$21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost, the approval of Biotres by Health Canada comes at an opportune time.

Biotricity Receives Health Canada Clearance for Biotres

Biotricity, Inc. (BTCY) Q3 2024 Earnings Call Transcript

Topline growth with better quality revenue mix Increase in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenue Improved margins Lower costs with improved selling expense Stronger path to breakeven REDWOOD CITY, CA / ACCESSWIRE / February 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the third quarter of fiscal 2024 year and (unaudited) ended December 31, 2023. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter was marked by record margins, lowered costs and increasing revenues, supporting our path towards positive cashflow.

Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024

Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago.

Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates

REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st

Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakeven Management to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024 REDWOOD CITY, CA / ACCESSWIRE / February 14, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency. For the Third Quarter of Fiscal Year 2024, the Company expects to announce: Record gross margins of 73% compared to the prior year quarter of 57% Improved operational efficiency, reflected in a reduction in operating expenses of over 30% The results for our third quarter will demonstrate year-over-year improvements in all key operating metrics- specifically in operational costs and gross margins.

Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024

Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platform Company has analyzed over 360 Billion heartbeats and helped diagnose over 200,000 patients Company is now focused on building predictive AI models to support earlier diagnoses and interventions Existing technologies are used in 500+ centers across the United States REDWOOD CITY, CA / ACCESSWIRE / January 23, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced the expanding development of its future Cardiac AI Cloud platform. The new platform is focused on predictive monitoring to help assist physicians and users to identify issues before they occur, supporting earlier interventions, reducing readmissions, and lowering healthcare costs.

Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats

Biotricity, Inc. (NASDAQ:BTCY ) Q2 2024 Earnings Conference Call November 14, 2023 6:00 PM ET Company Participants Debra Chen - IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Davin - H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2024 Financial Results and Business Update Conference Call.

Biotricity, Inc. (BTCY) Q2 2024 Earnings Call Transcript

Company reports Q2-FY24 revenue grew by 21.4% YOY to $2.9 million; continuing to advance toward positive cashflow Recurring technology fees, customer device sales, remain on an upward trend Reduced SG&A to $3.5 million, down 22% compared to same period last year Gross margins improve significantly to 69% from 54% compared to the same period last year Recurring Technology Fee Revenue - comprised 94.5% of total revenue with a 70% gross margin Net loss decreased 21% to $3.9 million Management will host its Q2 Fiscal Year 2024 Financial Results Call on Tuesday, November 14th at 6:00 p.m. ET REDWOOD CITY, CA / ACCESSWIRE / November 14, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2024 year and (unaudited) ended September 30, 2023.

Biotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024

Biotricity improves margins while lowering selling expenses and operating losses REDWOOD CITY, CA / ACCESSWIRE / November 10, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th

Company further expands its current product portfolio, making it the most comprehensive Remote Patient and Cardiac Monitoring portfolio globally. Company developed Biotres Pro with critical capability of cellular backup for connectivity Recently filed a patent application for its Biotres device as it seeks to redefine the cardiac care landscape REDWOOD CITY, CA / ACCESSWIRE / October 31, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced their expansion of the current Biotres product platform.

Biotricity Releases Another Groundbreaking Product: Biotres Pro

REDWOOD CITY, CA / ACCESSWIRE / October 10, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitoring sector of consumer healthcare, today announced its patent filing for the company's Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine's Best Inventions of 2022 stands as a "game changer" in the industries of personal heart and remote lifestyle monitoring.

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

This release corrects and replaces the headline in the the release that was disseminated October 3, 2023. The reason for this correction is to fix the title which previously stated "patient" rather than the correct word, "PATENT" REDWOOD CITY, CA / ACCESSWIRE / October 4, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device.

CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres Device

REDWOOD CITY, CA / ACCESSWIRE / October 3, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device. This patent protects Biotres' proprietary 3 channel technology, multiple sensors, architecture and compact form factor, a combination that has never been done before.

News for Biotricity Stock (BTCY)